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ABSTRACT
During a 2-year period (April 2005–March 2007), 31 intensive care unit (ICU) patients in a Greek hospital
were infected or colonised with imipenem-resistant isolates of Acinetobacter baumannii. Twelve patients
died, with imipenem-resistant A. baumannii infection contributing to the death of seven patients. The 31
representative A. baumannii isolates were multidrug-resistant and clustered in four distinct clones, each
of which contained different carbapenemase genes: clone I was predominant and contained blaVIM-1,
blaOXA-58 and the intrinsic blaOXA-66 gene; clone II contained blaVIM-4, blaOXA-58 and the intrinsic blaOXA-69
gene; clone III contained blaOXA-58 and the intrinsic blaOXA-69 gene; and clone IV contained only the
intrinsic blaOXA-66 gene. ISAba1 was not associated with the intrinsic blaOXA-51-like alleles, whereas ISAba3
was found upstream and downstream of blaOXA-58 in isolates of clone I, and upstream of blaOXA-58 in
isolates of clone III, but was not detected in isolates of clone II. PCR, curing and hybridisation
experiments indicated that the blaVIM alleles were chromosomally located, whereas the blaOXA-58 alleles
were plasmid-located. This study provides the first description of the clonal spread of multidrug-
resistant A. baumannii isolates carrying blaVIM-1 and blaVIM-4 metallo-b-lactamase genes, and revealed
that distinct carbapenem-resistant A. baumannii clusters bearing different carbapenemase genes may
emerge and cause severe infections, even in a well-defined regional hospital setting.
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INTRODUCTION
Acinetobacter baumanni is an opportunistic patho-
gen of increasing relevance in hospital infections
during the last 15 years. The organism causes a
wide range of infections, including pneumonia,
sepsis, wound infection, urinary tract infection
and post-neurosurgical meningitis, especially
among critically-ill patients in intensive care units
(ICUs) [1]. Extensive use of antimicrobial agents
within hospitals has contributed to the emergence
of multidrug-resistant A. baumannii strains that
exhibit resistance to a wide range of antibiotics,
including new-generation broad-spectrum b-lac-
tams, aminoglycosides and fluoroquinolones [2].
Carbapenems have potent activity against
acinetobacters and, until recently, were often
used to treat infections caused by multiresistant
A. baumannii isolates. However, acinetobacters
may develop resistance to carbapenems by vari-
ous mechanisms, including decreased permeabil-
ity, overexpression of efflux pumps and
production of carbapenemases [3]. In recent years,
carbapenem resistance has been attributed
increasingly to the production of carbapenemases,
which may be class D carbapenem-hydrolysing
oxacillinases or, less frequently, class B metallo-b-
lactamases (MBLs) [3]. The class D carbapene-
mases cluster into four groups, represented by
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OXA-23, OXA-24, OXA-58 and the intrinsic OXA-
51-like enzymes [3–7], while MBLs of the IMP,
VIM and SIM types have also been recognised
among A. baumannii isolates with reduced sus-
ceptibility to carbapenems [3,8–10].
Outbreaks of carbapenem-resistantA. baumannii
strains have been documented in diverse geo-
graphical areas, including America, Europe and
the Far East [2–5,11,12]. In Greek hospitals,
imipenem-non-susceptible A. baumannii strains
are isolated with increasing frequency from
clinical sources and have been associated with
outbreaks of infection in hospitals [13–15]. In
our own laboratory, susceptibility data have
revealed that a number of infections among
hospitalised patients were caused by A. baumannii
isolates that were resistant to carbapenems and
almost all alternative antimicrobial agents. As it
was evident that most isolates came from the
medical–surgical ICU of the hospital, a 2-year
study was initiated to study the characteristics of
this outbreak and the molecular epidemiology of
the carbapenem resistance.
MATERIALS AND METHODS
Setting, bacterial strains and surveillance procedures
The General Hospital of Serres is an acute-care regional
hospital in northern Greece, with 400 beds and a medical–
surgical ICU with a capacity of five patients, serving a
population of c. 200 000 inhabitants. The present study
included all imipenem-resistant A. baumannii isolates recov-
ered consecutively from the clinical specimens of separate
patients in the ICU of the hospital during the period April 2005
to March 2007. Isolates with an intermediate level of resistance
to imipenem (MIC 8 mg ⁄L) were also included. Only the first
patient isolate (one isolate per patient) obtained from cultures
taken >48 h after ICU admission were investigated. Clinical
and epidemiological histories were taken from each patient
colonised or infected with imipenem-resistant A. baumannii.
Data requested included demographical details, reason for
ICU admission, sources of isolation, colonised or infected sites,
and outcome in relation to A. baumannii infection [16]. Noso-
comial infections were defined according to standard CDC
definitions [17].
Following initiation of the study, the hospital infection
control team suggested restriction of carbapenem usage and
the use of stringent antiseptic techniques. The latter included
disinfection of the unit and the rigorous use of antiseptic
solutions before and between patient and equipment contact,
as well as before leaving the unit. In addition, environmental
surveillance was instituted, focusing on environmental sites
and equipment adjacent to the patients that should be free of
contamination. The samples were collected using pre-moist-
ened swabs that were then cultured on MacConkey agar
plates; any imipenem-resistant A. baumannii isolates recovered
from the environment were included in the study.
Identification and antimicrobial susceptibilities
Initial identification and susceptibility testing was performed
using the Microscan system (Dade Behring Inc., West Sacra-
mento, CA, USA). The isolates were also identified using the
API 20NE system (bioMe´rieux, Marcy l’E´toile, France), with
identification as A. baumannii confirmed by a biochemical
identification scheme and the analysis of partial rpoB gene
sequences [18].
Imipenem and meropenem MICs were determined by the
agar dilution method using CLSI interpretative criteria [19].
Imipenem-resistant isolates were also tested for resistance to
amikacin, ampicillin–sulbactam, aztreonam, ciprofloxacin,
cefepime, ceftazidime, colistin sulphate, gentamicin, piperacil-
lin–tazobactam, tigecycline and tobramycin using the agar
dilution method according to CLSI guidelines [19] (when
available). For tigecycline, the US Food and Drug Adminis-
tration recommendation was used (i.e., susceptible, £2 mg ⁄L;
resistant, ‡8 mg ⁄L). MBL production was tested phenotypi-
cally using MBL Etests (AB Biodisk, Solna, Sweden). Pseudo-
monas aeruginosa ATCC 27853 was used as a control in
susceptibility tests, and a VIM-type carbapenemase-producing
A. baumannii strain [10] was used as a control for the
phenotypic MBL assay.
Pulsed-field gel electrophoresis (PFGE) and cluster analysis
PFGE of ApaI-digested genomic DNA of A. baumannii isolates
was performed using a CHEF-DRIII system (Bio-Rad, Hemel
Hempstead, UK) according to previously described methods
[20], with the band patterns interpreted according to the
criteria of Tenover et al. [21]. ApaI macrorestriction patterns
were digitised and analysed using Quantity One Software
(Bio-Rad Laboratories Inc., Hercules, CA, USA) for calculating
Dice correlation coefficients and for cluster analysis using the
unweighted pair-group method with arithmetic averages.
PCR assays and DNA sequencing
Carbapenemase-encoding genes (blaIMP, blaVIM, blaSIM, blaOXA-
23-like, blaOXA-24-like, blaOXA-58-like) were sought by PCR using
consensus primers that were specific for each enzyme group
[9,10]. The isolates were also screened for intrinsic blaOXA-51-like
carbapenemase genes using partially degenerate primers
(sense, 5¢-TGAACATTAAAICACTCTT; antisense, 5¢-CTA
TAAAATACCTAATTGTT) that were designed to amplify an
825-bp product from all blaOXA-51-like alleles [14]. For integron
mapping, PCR assays combining primers specific for the
conserved 5¢-CS and 3¢-CS sequences with primers specific for
blaVIM genes were performed as described previously [10]. For
sequencing purposes, specific primers that amplify the entire
blaVIM gene were used [22]. PCR amplicons were purified
using ExoSAP-IT reagent (USB Corporation, Cleveland, OH,
USA), and both strands were sequenced using the standard
dideoxynucleotide method in an ABI Prism 377 DNA sequen-
cer (Applied Biosystems, Foster City, CA, USA). Sequence
similarity searches were carried out with the BLAST program
(http://www.ncbi.nlm.nih.gov/blast).
Insertion sequences ISAba1 and ISAba3, which have been
associated previously with expression of blaOXA-51-like and
blaOXA-58-like genes, respectively, were amplified as described
previously [6,7]. The genetic elements carrying the blaOXA-51-like
genes were investigated by PCR mapping using ISAba1 for-
ward ⁄OXA-51-like reverse and OXA-51-like forward ⁄ ISAba1
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reverse primers, while the genetic elements carrying the
blaOXA-58-like genes were investigated using ISAba3 for-
ward ⁄OXA-58 reverse and OXA-58 forward ⁄ ISAba3 reverse
primers.
Plasmid analysis, curing and hybridisation experiments
Plasmid analysis was performed using a ChargeSwitch Plas-
mid ER Mini Kit (Invitrogen, Carlsbad, CA, USA). Chromo-
somal and plasmid bands were extracted separately from
agarose 0.8% w ⁄v gels using a PureLink Quick Gel Extraction
Kit (Invitrogen); plasmid DNA was further purified using a
ChargeSwitch Pro Plasmid Miniprep Kit (Invitrogen) to
exclude chromosomal contamination. Eluted chromosomal
and plasmid DNA extracts were subjected to PCRs specific
for blaVIM and blaOXA-58 genes to check the location of each
gene. Plasmid DNA extracts were also used as templates in
PCRs specific for the 16S rDNA gene to confirm the exclusion
of chromosomal fragments.
Plasmid curing experiments were performed using ethidi-
um bromide at the maximum concentration (400 mg ⁄L) that
allowed the growth of isolates. The chromosomal location of
blaVIM alleles was also demonstrated by Southern blotting of
unsheared genomic DNA, followed by gene-specific hybridi-
sation with a blaVIM digoxigenin-labelled probe [23].
RESULTS
During the study period, 47 patients, who had
each been hospitalised for >2 days, became
infected or colonised with A. baumannii, with
imipenem-resistant A. baumannii isolates being
recovered from one or more clinical samples
submitted to the clinical laboratory from 31 of
these patients. The characteristics of these 31
patients and the properties of their imipenem-
resistant isolates are summarised in Table 1. The
age of the patients ranged from 22 to 83 years
(median, 68 years); 17 (54.8%) patients were male
and 14 (45.2%) were female. The main reasons for
admission to the ICU were pulmonary infection,
cerebrovascular incident, poly-trauma, heart dis-
ease and post-surgical complications (Table 1).
All patients were mechanically ventilated. Fifteen
(48.4%) patients were infected and 16 (51.6%)
were colonised, according to CDC definitions. The
sites of infection were the bloodstream (seven
Table 1. Case histories and properties of the isolates for intensive care unit (ICU) patients colonised or infected with
imipenem-resistant Acinetobacter baumannii
No.
Date of
isolation
(month ⁄ year)
Age
(years) ⁄
gender Reason for ICU admission Isolate source
Status ⁄
infection Outcome
PFGE
type
Antibiotic MIC (mg ⁄L)a
IPM MEM AZT SAM TGC COL
1 04 ⁄ 05 22 ⁄ F Poly-trauma Wound Colonised Discharged Ia 16 16 >256 16 1 0.5
2 04 ⁄ 05 64 ⁄M Septic shock Bronchial aspirate ⁄ blood Sepsis Died Ia 16 16 >256 16 0.25 1
3 04 ⁄ 05 77 ⁄M Poly-trauma ⁄ pneumonia Bronchial aspirate Colonised Discharged Ia 16 8 >256 16 1 0.25
4 04 ⁄ 05 67 ⁄ F Septic shock ⁄pneumonia Bronchial aspirate Pneumonia Discharged Ia 16 16 >256 16 2 0.5
5 05 ⁄ 05 68 ⁄ F Abdominal surgery ⁄pneumonia Bronchial aspirate ⁄ blood Sepsis Died Ia 32 16 >256 16 0.5 0.5
6 05 ⁄ 05 72 ⁄M Stroke ⁄ respiratory infection Urine Colonised Discharged II 16 8 16 32 8 0.5
7 05 ⁄ 05 75 ⁄ F Poly-trauma ⁄ pneumonia Wound Colonised Discharged III 32 32 32 16 0.5 0.5
8 05 ⁄ 05 72 ⁄M Cerebral haemorrhage ⁄pneumonia Bronchial aspirate Colonised Discharged Ia 16 16 >256 16 1 1
9 09 ⁄ 05 58 ⁄ F Stroke ⁄nephrotic syndrome Bronchial aspirate Colonised Diedb IV 8 8 >256 4 32 0.25
10 09 ⁄ 05 65 ⁄M Poly-trauma Bronchial aspirate Colonised Discharged IV 8 16 >256 16 4 0.12
11 09 ⁄ 05 68 ⁄ F Heart failure ⁄pneumonia Bronchial aspirate Pneumonia Died IV 32 32 >256 64 2 1
12 10 ⁄ 05 72 ⁄M Stroke Urine Colonised Discharged II 16 16 16 16 1 0.5
13 10 ⁄ 05 68 ⁄ F Pneumonia Bronchial aspirate Pneumonia Death Ib 32 32 >256 >128 0.5 0.5
14 04 ⁄ 06 68 ⁄ F Stroke Bronchial aspirate Colonised Discharged Ib 64 32 >256 32 1 1
15 04 ⁄ 06 64 ⁄M Stroke ⁄pneumonia Bronchial aspirate Colonised Discharged Ib 64 64 >256 32 1 1
16 07 ⁄ 06 75 ⁄ F Septic shock Bronchial aspirate Pneumonia Died Ia 32 32 >256 16 8 0.5
17 07 ⁄ 06 55 ⁄M Poly-trauma Blood Bacteraemia Discharged Ib 32 32 >256 32 4 0.5
18 07 ⁄ 06 75 ⁄M Cerebral haemorrhage ⁄
pneumonia
Blood ⁄ bronchial aspirate Sepsis Died II 8 4 16 4 8 0.5
19 09 ⁄ 06 65 ⁄ F Stroke ⁄pneumonia Bronchial aspirate Colonised Discharged Ib 32 32 >256 32 1 0.5
20 10 ⁄ 06 83 ⁄M Fracture ⁄ respiratory infection Blood Sepsis Died IV 32 32 >256 16 2 1
21 12 ⁄ 06 67 ⁄M Respiratory failure Bronchial aspirate Colonised Discharged Ib 32 32 >256 128 2 0.5
22 12 ⁄ 06 65 ⁄M Abdominal surgery Wound Wound infection Diedb Ia 16 16 >256 32 0.5 0.5
23 12 ⁄ 06 42 ⁄ F Poly-trauma Bronchial aspirate Colonised Discharged III 16 8 32 32 1 0.5
24 12 ⁄ 06 70 ⁄M Intestinal bleeding ⁄ febrility Blood Sepsis Discharged Ib 32 16 >256 16 1 0.5
25 01 ⁄ 07 24 ⁄M Poly-trauma Bronchial aspirate Colonised Discharged II 16 8 128 16 2 1
26 02 ⁄ 07 63 ⁄ F Respiratory failure Bronchial aspirate Colonised Discharged Ia 32 16 >256 16 1 1
27 02 ⁄ 07 78 ⁄M Pancreatitis ⁄ respiratory failure Bronchial aspirate Colonised Discharged II 16 16 64 16 0.5 0.5
28 02 ⁄ 07 76 ⁄M Septic shock Bronchial aspirate Pneumonia Diedb Ia 16 8 >256 8 1 0.5
29 03 ⁄ 07 71 ⁄ F Heart failure ⁄ cerebral
haemorrhage
Blood Bacteraemia Diedb Ia 16 8 >256 8 1 0.5
30 03 ⁄ 07 72 ⁄ F Abdominal surgery ⁄pneumonia IV catheter ⁄ bronchial aspirate Pneumonia Discharged IV 16 8 >256 16 2 0.5
31 03 ⁄ 07 58 ⁄M Poly-trauma Bronchial aspirate ⁄wound Wound infection Diedb Ia 16 16 >256 16 0.5 0.5
aAll isolates were resistant to ceftazidime, cefepime, ciprofloxacin, piperacillin–tazobactam, amikacin, gentamicin, netilmicin and tobramycin.
bDeath was not related to A. baumannii infection.
AZT, aztreonam; COL, colistin; IMP, imipenem; MEM, meropenem; SAM, ampicillin–sulbactam; TGC, tigecycline; M, male; F, female; PFGE, pulsed-field gel electrophoresis;
IV, intravenous.
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patients), the respiratory tract (six patients), and a
surgical wound (two patients).
For infections caused by ampicillin–sulbactam-
susceptible isolates, the patients received
intravenous colistin in combination with
ampicillin–sulbactam for bloodstream and wound
infections, while nebulised colistin in combination
with intravenous ampicillin–sulbactam was
administered for respiratory tract infections. In
cases where infections were caused by ampicillin–
sulbactam-resistant isolates, ampicillin–sulbactam
was replaced with high intravenous doses of
imipenem. Twelve of the 31 patients died, with
A. baumannii infection contributing to death in
seven cases (Table 1). Analysis of 45 environmen-
tal samples obtained during the study period
yielded three imipenem-resistant A. baumannii
isolates; one from the floor of the ICU, one from
the bed of an ICU patient, and one from the
external site of the ventilator tube of an infected
patient.
Imipenem and meropenem MICs for the 31
clinical isolates ranged between 4 and 64 mg ⁄L
(Table 1). The isolates were multidrug-resistant,
exhibiting resistance to ciprofloxacin, aminogly-
cosides and b-lactams, but showed some suscep-
tibility to tigecycline, ampicillin–sulbactam and
aztreonam, for which 27, 21 and three isolates,
respectively, were defined as susceptible or inter-
mediate. All isolates were susceptible to colistin.
PFGE of the imipenem-resistant clinical isolates
revealed four distinct clonal types (Table 1).
Nineteen isolates belonged to a predominant
clone (type I), two clones (types II–IV) contained
five isolates, and one clone (type III) contained
two isolates. The 19 isolates in the major clone
were divided into two clonal subtypes (Ia and Ib;
83% similar), which contained 12 and seven
isolates, respectively. Two of the three environ-
mental isolates belonged to subtype Ia, while the
third belonged to type II.
Following initiation of the prospective study in
April 2005, the reduction in usage of carbapen-
ems, combined with the other infection control
measures that were instituted, resulted in an
absence of further infections caused by imipe-
nem-resistant A. baumannii in June–August 2005
and in November 2005 to March 2006. However,
carbapenem usage subsequently returned almost
to previous levels, and this may have contributed
to the reappearance in the ICU of the predomi-
nant clone I and the three other clones (Fig. 1).
MBL Etests were positive for 21 of the 31
imipenem-resistant clinical isolates; however,
PCRs revealed that 24 isolates were positive for
a blaVIM gene (Table 2). All isolates were negative
for the remaining MBL genes (blaIMP and blaSIM),
as well as for blaOXA-23-like and blaOXA-24-like genes.
A blaOXA-58-like gene was amplified from 26
isolates, while an intrinsic blaOXA-51-like gene was
amplified from all 31 clinical isolates. Sequencing
of blaVIM amplicons identified a blaVIM-1 allele in
19 isolates (all were MBL-positive according to
Etests) and a blaVIM-4 allele in five isolates (two
were positive and three were negative according
to MBL Etests). In all cases, the blaVIM alleles were
inserted in class 1 integron variable structures
(data not shown).
Sequencing of the blaOXA-51-like amplicons
revealed blaOXA-66 (24 isolates) and blaOXA-69
(seven isolates), while all 26 blaOXA-58-like alleles
were the classic blaOXA-58 allele. It was of interest
that isolates from each one of the four clones
harboured a different pattern of carbapenemase
genes: isolates of clone I contained blaVIM-1,
blaOXA-58 and the intrinsic blaOXA-66 gene; isolates
of clone II contained blaVIM-4, blaOXA-58 and the
intrinsic blaOXA-69 gene; isolates of clone III con-
tained blaOXA-58 and the intrinsic blaOXA-69 gene;
and isolates of clone IV contained only the intrin-
sic blaOXA-66 gene (Table 2). The three environ-
mental isolates contained the carbapenemases
that were detected in clinical isolates of clone I
(two isolates) and clone II (one isolate).
Three imipenem-susceptible (MIC £4 mg ⁄L)
A. baumannii isolates obtained during the study
Fig. 1. Occurrence of patients infected or colonised with
different clones of imipenem-resistant Acinetobacter bau-
mannii in the medical–surgical intensive care unit between
April 2005 and March 2007.
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period from other patients hospitalised in the ICU
were negative for all carbapenemase genes except
the intrinsic blaOXA-51-like gene. These three iso-
lates belonged to two clonal types that were
distinct from those detected among imipenem-
resistant isolates (data not shown).
PCR for the insertion sequence ISAba1 was
positive for all 34 imipenem-resistant isolates, but
PCR mapping revealed that it was not associated
with the blaOXA-51-like alleles. PCR for the insertion
sequence ISAba3 was positive only for imipenem-
resistant isolates of clones I and III. ISAba3 was
found upstream and downstream of the blaOXA-58
gene in blaVIM-1- and blaOXA-58-producing isolates
(clone I), but only upstream of the blaOXA-58 gene
in isolates belonging to clone III (Table 2).
Three isolates, representative of each of the
three clonal types that produced blaVIM and ⁄ or
blaOXA-58 genes, were analysed for their plasmid
content; all three isolates carried a large plasmid
of 45–70 MDa, but small plasmid bands were also
detected (data not shown). The large plasmids
and the chromosomal DNA band of each isolate
were extracted from the agarose gel and used as
templates in PCRs for the blaVIM and ⁄ or blaOXA-58
genes. The results suggested that the blaVIM alleles
were located on the chromosome, whereas the
blaOXA-58 alleles were located on the plasmid
DNA. Consistent with these findings, the blaOXA-58
gene was cured from three isolates harbouring
blaOXA-58, while hybridisation of intact genomic
DNA with the blaVIM probe indicated a chromo-
somal location for blaVIM in two isolates.
DISCUSSION
The impact of imipenem-resistant A. baumannii on
ICU-acquired infection may be substantial. The
occurrence of a predominant multiresistant
A. baumannii antibiotype in a well-defined clinical
setting may lead to the assumption that an
outbreak is caused by a single disseminated clone
[2,5,11,13]. However, the present study revealed
the emergence of four imipenem-resistant A. bau-
mannii clones producing different carbapenemas-
es in the ICU of a Greek regional hospital. During
the first period of the investigation (April–May
2005), all the isolates that infected or colonised the
patients belonged to clonal type I, except for two
isolates that belonged to clonal types II and III,
respectively. After reinforcement of the barrier
methods and cleaning protocols in April 2005, no
patients infected or colonised with imipenem-
resistant isolates were detected for the next
3 months (June–August 2005). However, a new
clone (type IV) was introduced and disseminated
in September 2005, followed in October 2005 by
the reappearance of the predominant clones I and
II. All clonal types also reappeared after the
second period (November 2005 to March 2006), in
which imipenem-resistant isolates were not
recovered from patients’ clinical samples. It is
also of interest that the infection control measures
were reinforced in the first trimester of 2007,
which resulted in an absence of imipenem-resis-
tant A. baumannii infections after the study period
ended in March 2007 (data not shown).
Carbapenemase-producing strains of A. bau-
mannii have been involved in outbreaks in
Europe, Asia and both North and South America
[2,3]. The carbapenemases produced by
such strains are mostly class D oxacillinases
[3–5,13,14], although metallo-enzymes of the
IMP, VIM and SIM families have also been
detected in some well-defined geographical re-
gions [3,12]. Among the latter enzymes, the IMP-1
and VIM-2 types have been associated with
clusters of carbapenem-resistant A. baumannii iso-
lates [8,24,25], and the sporadic production of
VIM-1 in clonally distinct A. baumannii isolates
from Greece has been reported previously [10].
The present study is the first to describe the clonal
Table 2. Results of molecular analysis of 31 clinical and three environmental imipenem-resistant isolates of Acinetobacter
baumannii
PFGE type
No. of
clinical
isolates
No. of
environmental
isolates
PCR
ISAba1
unrelated blaOXA-51-like
ISAba3
upstream
ISAba3
downstream blaOXA-58-like blaOXA-23-like blaOXA-24-like blaVIM
I 19 2 + OXA-66 + + + ) ) VIM-1
II 5 1 + OXA-69 ) ) + ) ) VIM-4
III 2 ) + OXA-69 + ) + ) ) )
IV 5 ) + OXA-66 ) ) ) ) ) )
PFGE, pulsed-field gel electrophoresis.
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dissemination of VIM-1-producing A. baumannii
isolates in a hospital environment. The isolates
carrying blaVIM-1 also had an MBL gene and 59-bp
elements that were identical to those described
originally in P. aeruginosa [26], and subsequently
among other Gram-negative bacteria in Greece
[27]. This apparent spread could have been
facilitated by the extensive use of carbapenems
against the multidrug-resistant Gram-negative
bacteria that have been isolated frequently from
patients in the ICU studied. In addition, the
detection of common clones among environmen-
tal and clinical imipenem-resistant isolates of
A. baumannii suggests that environmental con-
tamination might have contributed to the diffi-
culty in restricting the spread of these organisms
in the unit. It is possible that some environmental
reservoirs may have remained undetected using
the swab technique [28]. Nevertheless, environ-
mental surveillance and strict antiseptic tech-
niques may have contributed to the reduced
spread of these bacteria for periods during and
after the end of the survey.
Three additional imipenem-resistant clones
were detected during this prospective study, one
of which carried blaVIM-4, which is a point mutant
of blaVIM-1 and was first identified in a carbape-
nem-resistant clinical isolate of P. aeruginosa in
Greece [29]. This variant has now been detected in
several P. aeruginosa clones in Greece [30], as well
as among pseudomonads and enterobacteria in
several other European countries, Tunisia and
Australia [31–34]. However, to our knowledge,
the present study is the first report of A. bauman-
nii isolates carrying blaVIM-4. Nevertheless, these
clonal isolates exhibited relatively low levels of
resistance to carbapenems, perhaps attributable to
the fact that the companion blaOXA-58 gene was not
associated with ISAba3 promoter sequences. It has
been shown previously that OXA-58 has weak
carbapenemase activity and plays a role in carb-
apenem resistance in A. baumannii only when
blaOXA-58 is up-regulated and highly expressed [6].
Much of the resistance in the isolates studied
could also depend on impermeability or other
combined mechanisms that simultaneously affect
resistance to other antibiotics, e.g., expanded-spec-
trum cephalosporinases [3]. Thus, no acquired
carbapenemases were detected in five clinical
isolates that exhibited resistance to carbapenems,
and expression of the intrinsic blaOXA-51-like alleles
in these isolates was not activated by the presence
of ISAba1 upstream of the carbapenemase gene [7].
The incidence and spread of carbapenem-resistant
clones in this ICU, which was associated with a
fatal outcome in several cases, remains a concern
and merits continuation of the surveillance pro-
gramme and the infection control measures.
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